Argenta Discovery and Porsolt Join Forces to Provide CNS and Pain Contract Drug Discovery Services
News May 20, 2009
Argenta Discovery and Porsolt have announced they have entered into an alliance to provide unparalleled CNS and pain drug discovery services and expertise on a fee-for-service basis.
The collaboration enables Argenta and Porsolt to undertake fully integrated CNS and pain-focused drug discovery programmes for their clients, from hit identification to development candidate nomination. Both companies bring a wealth of ‘Big Pharma’ industry based experience and know-how in CNS and pain research. This alliance will leverage those key skills for its partners to ensure the rapid generation of high quality development candidates.
Dr. Christopher Ashton, CEO of Argenta said, "Argenta has undertaken many successful medicinal chemistry-driven CNS and pain contract drug discovery research projects, but we have been looking at ways of enhancing our capabilities in these important therapeutic areas. Argenta has partnered with Porsolt to provide clients with dedicated access to specialist CNS and pain models and expertise, offered by a world leader in the field. We have several ongoing contract research programmes in these therapeutic areas and a number of projects in the pipeline which are likely to benefit from Porsolt’s support and know-how. This alliance will enable Argenta to offer an even better integrated drug discovery service in the future. We are looking forward to working with Porsolt.”
Dr Mark Duxon, CEO of Porsolt added, “Porsolt is delighted to be entering into a partnership with Argenta to deliver full lead optimisation drug discovery on a contract research basis. Porsolt have recently announced a significant laboratory expansion in France and the Argenta partnership fits with our strategy of offering a diverse array of deal structure opportunities to suit the broad range of our clients’ needs. Indeed, our increased business flexibility is entirely complementary to our client-oriented scientific expertise. Porsolt has always sought to deliver quality scientific solutions tailored to client needs. In this respect, we believe we have found a like minded partner in Argenta”.
Where there is a client need for outsourcing fully integrated drug discovery programmes for CNS and pain targets, Argenta and Porsolt offer a seamless drug discovery platform to the pharmaceutical industry, from hit identification to drug candidate selection. Should a client not be interested in a solution of this nature, both Porsolt and Argenta will continue to operate independently, offering their stand-alone contract research services spanning all therapeutic areas and drug target classes.
Worms Exhibit Fear and Respond to Anti-anxiety MedsNews
A team of investigators has uncovered new clues about the mechanisms of fear and anxiety through an unlikely creature: the tiny nematode worm.READ MORE
New Chemical Synthesis Process: Synergy of Two Catalysts in One FlaskNews
Researchers report the one-step synthesis of a ketone from an aldehyde by the combination of thiazolium N-heterocyclic carbene and palladium/bisphosphine catalysts in one flask. The two catalysts function in a synergistic manner. This study is expected to lead to new synthesis processes of precursor compounds for medications.READ MORE
Synthesis of Drug-Like Molecules Simplified Using New Cross-Coupling MethodNews
Researchers have designed a new molecule-building method. The technique, described recently in the journal Science, paves the way toward other new chemical reactions and facilitates the synthesis of pharmaceutically-relevant molecules.READ MORE